Daily Endocrinology Research Analysis
Three high-impact endocrinology papers stood out today: a 2.99-million-person nationwide cohort linking glycemic status in non-diabetics/prediabetes to pancreatic cancer risk; a meta-analysis of over 30,000 patients showing novel MRAs reduce major cardiovascular events in type 2 diabetes; and a Danish national DXA dataset revealing clinically driven but incomplete osteoporosis case-finding. Together, these studies inform cancer prevention, cardiometabolic therapy, and population-level bone healt
Summary
Three high-impact endocrinology papers stood out today: a 2.99-million-person nationwide cohort linking glycemic status in non-diabetics/prediabetes to pancreatic cancer risk; a meta-analysis of over 30,000 patients showing novel MRAs reduce major cardiovascular events in type 2 diabetes; and a Danish national DXA dataset revealing clinically driven but incomplete osteoporosis case-finding. Together, these studies inform cancer prevention, cardiometabolic therapy, and population-level bone health strategies.
Research Themes
- Cancer risk modulation by glycemic status
- Cardiovascular outcomes with mineralocorticoid receptor antagonists in T2DM
- Population registries to optimize osteoporosis care
Selected Articles
1. Lower glycemic status was associated with pancreatic cancer risk in prediabetes, but not in diabetes: A nationwide cohort study.
In a nationwide cohort of 2,993,519 adults with repeated fasting glucose assessments, higher fasting glucose within the non-diabetic range was associated with a higher incidence of pancreatic cancer, whereas no dose-response pattern was observed. New-onset and known diabetes groups had generally higher incidence than non-diabetics, but pancreatic cancer risk did not vary by glycemic control in established diabetes.
Impact: This exceptionally large cohort links glycemic status in non-diabetic populations to pancreatic cancer risk, informing prevention strategies at the prediabetes stage. It challenges the assumption that risk modulation by glycemia is confined to overt diabetes.
Clinical Implications: For individuals without diabetes, maintaining optimal fasting glucose may be important for pancreatic cancer prevention. Risk stratification efforts in prediabetes should consider sustained elevations in fasting glucose when counseling and planning surveillance or lifestyle interventions.
Key Findings
- Among non-diabetics, moderately or poorly controlled fasting glucose categories had higher pancreatic cancer incidence versus well-controlled.
- No clear dose-response relationship between glycemic categories and pancreatic cancer incidence was observed.
- New-onset and known diabetes groups had generally higher pancreatic cancer incidence than non-diabetics, but risk did not vary by glycemic control status within diabetes.
Methodological Strengths
- Very large nationwide cohort with repeated annual fasting glucose measurements
- Stratification by diabetes status and glycemic control categories
Limitations
- Observational design limits causal inference and residual confounding may persist
- Glycemic exposure assessed via fasting glucose categories; lack of HbA1c or continuous glycemic measures in the abstracted description
Future Directions: Prospective studies with detailed glycemic metrics (including HbA1c and time-in-range) and mechanistic work on hyperglycemia-related carcinogenesis could clarify causality and thresholds for risk.
INTRODUCTION: Hyperglycemia or diabetes mellitus (DM) is a well-known risk factor for pancreatic cancer, but it is uncertain whether well-controlled glycemic status can affect the pancreatic cancer incidence rate. METHODS: This study used 2,993,519 individuals who underwent four consecutive national annual health screenings between 2009 and 2013. The study participants were divided into three groups: nondiabetes mellitus (non-DM), new-onset DM, and known DM. Each group was further subcategorized based on the fasting blood glucose (FBG) levels and use of antidiabetic medication: well-controlled (<100 mg/dL), moderately controlled (100-125), or poorly controlled (>126). RESULTS: During a median follow-up of 6.3 years, the incidence rate of pancreatic cancer in the non-DM group significantly increased in the moderately controlled group compared with that in the well-controlled group, regardless of whether the FBG level was recently or initially elevated. However, no dose-response relationship was observed between glucose control status and pancreatic cancer incidence, although the incidence of pancreatic cancer in the new DM and known DM groups was generally higher than that in the non-DM group. CONCLUSION: The pancreatic cancer incidence rate in the non-DM group significantly increased in the poorly controlled group. These findings suggest that in populations without DM, maintaining optimal glucose control may be associated with a lower risk of developing pancreatic cancer.
2. Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients.
Across 18 RCTs with 30,103 participants, MRAs reduced MACE (OR 0.81), cardiovascular mortality (OR 0.86), and heart failure hospitalization (OR 0.77) in T2DM. Network pharmacology suggests distinct pathway engagement for steroidal versus non-steroidal MRAs.
Impact: This synthesis consolidates high-certainty evidence that MRAs confer broad cardiovascular benefits in T2DM and contextualizes mechanistic differences between drug classes.
Clinical Implications: MRAs, particularly non-steroidal agents, should be considered in T2DM patients at cardiovascular risk to reduce MACE and heart failure hospitalizations, aligned with a growing evidence base.
Key Findings
- MRAs reduced major adverse cardiovascular events in T2DM (OR 0.81, 95% CI 0.75–0.86).
- MRAs lowered cardiovascular mortality (OR 0.86) and heart failure hospitalization (OR 0.77).
- Network pharmacology indicates steroidal MRAs may act via IL-17 and relaxin pathways, while non-steroidal MRAs modulate Ras and relaxin signaling.
Methodological Strengths
- Inclusion of 18 randomized controlled trials totaling over 30,000 participants
- Complementary mechanistic exploration via network pharmacology
Limitations
- Heterogeneity across trials and inclusion of subgroup analyses may introduce bias
- Lack of patient-level data and reliance on network pharmacology limits mechanistic certainty
Future Directions: Head-to-head RCTs comparing steroidal versus non-steroidal MRAs in T2DM and mechanistic biomarker studies could refine patient selection and combination strategies.
AIM: To evaluate the clinical efficacy and explore the potential mechanisms of novel mineralocorticoid receptor antagonists (MRAs) in reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). METHODS: Randomized controlled trials (RCTs), including relevant subgroup analyses, of steroidal MRAs (eplerenone, canrenone) and non-steroidal MRAs (finerenone, esaxerenone) in T2DM patients were identified through systematic searches of English and Chinese databases. Meta-analysis was performed to assess clinical outcomes, and network pharmacology was used to explore underlying molecular mechanisms. RESULT: 18 RCTs (including relevant subgroup analyses) involving 30,103 participants were included. MRAs significantly reduced MACE risk (OR = 0.81, 95 % CI: 0.75-0.86; P < 0.00001). MRAs also significantly decreased cardiovascular mortality (OR = 0.86, 95 % CI: 0.77-0.97; P = 0.01) and hospitalization for heart failure (OR = 0.77, 95 % CI: 0.68-0.87; P < 0.0001). Network pharmacology identified that steroidal MRAs mainly act via IL-17 and relaxin signaling pathways, targeting MAPK10, GSK3B, PTGS2, NOS2, and MMP1. Non-steroidal MRAs primarily modulate Ras and relaxin pathways, involving targets such as EGFR and PIK3C. CONCLUSIONS: This study provides high-certainty evidence supporting MRAs in reducing MACE and heart failure hospitalization, and moderate-certainty evidence for benefits on cardiovascular mortality. Cardioprotective effects may involve Ras, IL-17, and relaxin signaling.
3. The Danish Nationwide osteoporosis cohort trials environment (NOCTE) - a DXA dataset for the 1900-1960 birth cohort.
The NOCTE dataset includes 263,651 first-time DXA recipients (2010–2022) matched 1:5 to non-scanned controls, revealing that DXA referral in Denmark is clinically driven (fracture history, glucocorticoids, comorbidity) rather than socioeconomic. A substantial diagnostic gap remains, as many high-risk individuals with prior fractures were never scanned.
Impact: This national resource exposes a systematic diagnostic gap in osteoporosis case-finding and offers a platform to design and evaluate targeted interventions and pragmatic trials.
Clinical Implications: Health systems can leverage NOCTE data to improve DXA targeting—particularly ensuring scans after major osteoporotic fractures—and to reduce inequities by maintaining clinically driven referrals.
Key Findings
- 263,651 individuals received first DXA; at baseline, osteoporosis was present in 33% of women and 17% of men.
- DXA recipients had similar socioeconomic but markedly higher clinical risk profiles versus matched non-scanned controls.
- A diagnostic gap persists: many high-risk individuals with prior fractures did not undergo DXA.
Methodological Strengths
- Nationwide linkage of DXA data to comprehensive registries with 1:5 matched controls
- Large sample size enabling robust characterization of referral patterns
Limitations
- Generalizability outside Denmark may be limited
- Descriptive observational design cannot assess the impact of DXA on outcomes within this report
Future Directions: Use NOCTE to design targeted outreach (e.g., post-fracture DXA triggers) and pragmatic trials to close the diagnostic gap and improve fracture prevention.
BACKGROUND: Osteoporosis is a common, underdiagnosed condition causing increased risk of fracture. While dual-energy X-ray absorptiometry (DXA) is the diagnostic standard, this may not be successfully targeted to individuals at the highest risk. This study presents an extensive nationwide dataset characterizing DXA-scanning practices in Denmark. METHODOLOGY: In this study, we identified all Danish residents from the birth cohort 1900-1960, with a first DXA scan between 2010-2022 to form the Nationwide Osteoporosis Cohort Trials Environment (NOCTE) dataset. These individuals were matched 1:5 to a non-scanned reference population by birth year, sex, and region of residence. Individual data were linked to national registers for comprehensive sociodemographic and clinical information. RESULTS: The final cohort included 263,651 individuals who underwent DXA scanning. At their first scan, 33% of women and 17% of men had osteoporosis. Compared to the matched reference, the scanned cohort had similar socioeconomic profiles but substantially different clinical profiles. Scanned individuals had a much higher prevalence of prior major osteoporotic fractures, prior systemic glucocorticoid exposure, and overall comorbidity burden. CONCLUSION: Referral for DXA in Denmark is driven by clinical risk rather than socioeconomic status, reflecting an equitable resource allocation. However, a significant diagnostic gap persists, as many high-risk individuals with prior fractures did not receive a DXA. The NOCTE cohort is a new, powerful resource for developing strategies to help close this gap.